<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Tumors of female reproductive system</journal-id><journal-title-group><journal-title xml:lang="en">Tumors of female reproductive system</journal-title><trans-title-group xml:lang="ru"><trans-title>Опухоли женской репродуктивной системы</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1994-4098</issn><issn publication-format="electronic">1999-8627</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">550</article-id><article-id pub-id-type="doi">10.17650/1994-4098-2017-13-3-41-56</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>MAMMOLOGY. CLINICAL GUIDELINES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>МАММОЛОГИЯ. КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">DIAGNOSIS AND TREATMENT OF BREAST CANCER IN SITU. RUSSIAN ASSOCIATION OF ONCOLOGICAL MAMMOLOGY CLINICAL GUIDELINES (PROJECT)</article-title><trans-title-group xml:lang="ru"><trans-title>ДИАГНОСТИКА И ЛЕЧЕНИЕ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ IN SITU. КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ РОССИЙСКОГО ОБЩЕСТВА ОНКОМАММОЛОГОВ (ПРОЕКТ)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Semiglazov</surname><given-names>V. V.</given-names></name><name xml:lang="ru"><surname>Семиглазов</surname><given-names>В. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, member of the RAOM board.</p><p>6–8 L’va Tolstogo St., Saint Petersburg 197022; 68 Leningradskaya St., Pesochnyi Settlement, Saint Petersburg 197758 </p></bio><bio xml:lang="ru"><p>Доктор медицинских наук, член правления РООМ.</p><p>197022 Санкт-Петербург, ул. Льва Толстого, 6–8; Россия, 197758 Санкт-Петербург, пос. Песочный, ул. Ленинградская, 68</p></bio><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Acad. I.P. Pavlov First Saint Petersburg State Medical University</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">N.N. Petrov National Medical Research Oncology Center, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Петрова» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2017-09-06" publication-format="electronic"><day>06</day><month>09</month><year>2017</year></pub-date><volume>13</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>41</fpage><lpage>56</lpage><history><date date-type="received" iso-8601-date="2017-09-06"><day>06</day><month>09</month><year>2017</year></date><date date-type="accepted" iso-8601-date="2017-09-06"><day>06</day><month>09</month><year>2017</year></date></history><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://ojrs.abvpress.ru/ojrs/article/view/550">https://ojrs.abvpress.ru/ojrs/article/view/550</self-uri><abstract xml:lang="en"><p>One of the first and foremost tasks of the Russian Association of Oncological Mammology (RAOM) is to develop clinical guidelines on diagnosis and treatment of breast cancer taking into account international experience. The guidelines must also be applicable in all regions of the Russian Federation allowing all Russian specialist to be informed about the latest strategies of diagnosis and treatment.</p><p>These clinical guidelines are based on the following consensus documents:</p><p>• St. Gallen Expert Panel (2011, 2013),</p><p>• Expert Panel of the IX International Conference “White Nights – 2012”,</p><p>• Expert Panel of the RAOM (2013),</p><p>• International consensus on treatment of metastatic breast cancer ABC 1,</p><p>• NCCN (2014)  and ESMO (2011) practical guidelines,</p><p>as well as the results of large international randomized studies conducted in partnership with Russian oncological centers.</p><p>The guidelines take into account the results of the analysis of a cumulative database on breast cancer treatment methods performed at</p><p>• N.N. Petrov National Medical Research Oncology Center, Ministry of Health of Russia,</p><p>• Saint  Petersburg City Clinical Oncological  Dispensary.</p><p>Our guidelines are based on methods that are available everywhere in the Russian Federation, treatment schemes and drugs are presented in accordance with the marketing authorization of the Ministry of Health of Russia, drug therapy takes into account biological subtypes of breast cancer, different courses of the disease as well as nonuniform situation with drug availability in various regions of the Russian Federation.</p><p>Obviously, such materials cannot serve as a direct guide for action (every patient’s disease is different), but they can lend a helping hand to a doctor striving to treat patients according to the latest achievements of modern oncology.</p><p>All-Russian non-governmental organization Russian Association of Oncological Mammology. President of the RAOM, corresponding member of the RAS, Prof. V.F. Semiglazov; Vice-President of the RAOM, corresponding member of the RAS, Prof. G.M. Manikhas; Executive Director of the RAOM R.M. Paltuev, PhD.</p></abstract><trans-abstract xml:lang="ru"><p>Одна из первоочередных задач Российского общества онкомаммологов (РООМ) – разработать клинические рекомендации по диагностике и лечению рака молочной железы (РМЖ), в которых учтен международный опыт и при этом учтена доступность использования во всех регионах Российской Федерации, чтобы все российские специалисты были в курсе последних диагностических и лечебных стратегий.</p><p>Представленные клинические рекомендации основаны на согласительных документах:</p><p>• Панели экспертов Сан-Галлена (2011, 2013),</p><p>• совета экспертов IX Международной конференции «Белые ночи – 2012»,</p><p>• совета экспертов РООМ (2013),</p><p>• Международного консенсуса по лечению метастатического рака молочной железы ABC 1,</p><p>• Практическом руководстве NCCN (2014) и ESMO (2011),</p><p>а также на результатах крупных международных рандомизированных исследований, проходящих при участии российских онкологических центров.</p><p>В рекомендациях учтены результаты анализа кумулятивной базы данных по методам лечения РМЖ, проведенного:</p><p>• в ФБГУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Петрова» Минздрава России,</p><p>• СПб  ГБУЗ «Городской клинический онкологический диспансер».</p><p>Наши рекомендации базируются на методиках, доступных к использованию на всей территории Российской Федерации, схемы лечения и препараты даны в соответствии с регистрационными удостоверениями Минздрава России, лекарственная терапия представлена с учетом биологических подтипов РМЖ, различных вариантов течения заболевания, а также неодинаковой ситуации с лекарственным обеспечением в различных регионах РФ.</p><p>Конечно, подобные материалы не могут быть прямым руководством  к действию (болезнь каждой пациентки имеет свои особенности), но они могут быть хорошим подспорьем в работе врача, стремящегося лечить пациентов согласно самым последним достижениям современной онкологии.</p><p>Общероссийская общественная организация «Российское общество онкомаммологов» (РООМ). Президент РООМ – член-корр. РАН, проф. В.Ф. Семиглазов; Вице-президент РООМ – член-корр. РАН, проф. Г.М. Манихас; Исполнительный директор РООМ – к. м. н. Р.М. Палтуев.</p></trans-abstract><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1. Timbrell S., Al-Himdani S., Shaw O. et al. Comparison of local recurrence after simple and skin-sparing mastectomy performed in patients with ductal carcinoma in situ. Ann Surg Oncol 2017;24:1071–6. DOI: 10.1245/s10434-016-5673-6. PMID: 27837296.</mixed-citation><mixed-citation xml:lang="ru">Timbrell S., Al-Himdani S., Shaw O. et al. Comparison of local recurrence after simple and skin-sparing mastectomy performed in patients with ductal carcinoma in situ. Ann Surg Oncol 2017;24:1071–6. DOI: 10.1245/s10434-016-5673-6. PMID: 27837296.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2. Lagios M.D. Heterogeneity of duct carcinoma in situ (DCIS): relationship of grade and subtype analysis to local recurrence and risk of invasive transformation. Cancer Letters 1995;90(1):97–102. PMID: 7720048.</mixed-citation><mixed-citation xml:lang="ru">Lagios M.D. Heterogeneity of duct carcinoma in situ (DCIS): relationship of grade and subtype analysis to local recurrence and risk of invasive transformation. Cancer Letters 1995;90(1):97–102. PMID: 7720048.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3. Silverstein M.J. Ductal carcinoma in situ of the breast. Baltimore: Williams and Wilkins, 1997. P. 363–364.</mixed-citation><mixed-citation xml:lang="ru">Silverstein M.J. Ductal carcinoma in situ of the breast. Baltimore: Williams and Wilkins, 1997. P. 363–364.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4. Silverstein M.J. Ductal carcinoma in situ of the breast. Annu Rev Med 2000;51:17–32. DOI: 10.1146/annurev.med.51.1.17. PMID: 10774450.</mixed-citation><mixed-citation xml:lang="ru">Silverstein M.J. Ductal carcinoma in situ of the breast. Annu Rev Med 2000;51:17–32. DOI: 10.1146/annurev.med.51.1.17. PMID: 10774450.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Correa C., McGale P., Taylor C. et al. Overview of the randomized trials of radiotherapyin ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr 2010;41:162–77. DOI: 10.1093/jncimonographs/lgq039. PMID: 20956824.</mixed-citation><mixed-citation xml:lang="ru">Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Correa C., McGale P., Taylor C. et al. Overview of the randomized trials of radiotherapyin ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr 2010;41:162–77. DOI: 10.1093/jncimonographs/lgq039. PMID: 20956824.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6. Van Zee K.J., Subhedar P., Olcese C. et al. Relationship between margin width and recurrence of ductal carcinoma in situ: analysis of 2996 women treated with breast-conserving surgery for 30 years. Ann Surg 2015;262(4):623–31. DOI: 10.1097/SLA.0000000000001454. PMID: 26366541.</mixed-citation><mixed-citation xml:lang="ru">Van Zee K.J., Subhedar P., Olcese C. et al. Relationship between margin width and recurrence of ductal carcinoma in situ: analysis of 2996 women treated with breast-conserving surgery for 30 years. Ann Surg 2015;262(4):623–31. DOI: 10.1097/SLA.0000000000001454. PMID: 26366541.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">7. Marinovich M.L., Azizi L., Macaskill P. et al. The association of surgical margins and local recurrence in women with ductal carcinoma in situ treated with breast-conserving therapy: A metaanalysis. Ann Surg Oncol 2016;23(12):3811–21. DOI: 10.1245/s10434-016-5446-2. PMID: 27527715.</mixed-citation><mixed-citation xml:lang="ru">Marinovich M.L., Azizi L., Macaskill P. et al. The association of surgical margins and local recurrence in women with ductal carcinoma in situ treated with breast-conserving therapy: A metaanalysis. Ann Surg Oncol 2016;23(12):3811–21. DOI: 10.1245/s10434-016-5446-2. PMID: 27527715.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">8. Morrow M., Van Zee., Solin L. et al. Society of Surgical Oncology – American Society for Radiation Oncology – American Society of Clinical Oncology consensus Guideline on margins for breast-conserving surgery with wholebreast irradiation in ductal carcinoma in situ. J Clin Oncol 2016;34(33):4040–6. DOI: 10.1200/JCO.2016.68.3573. PMID: 27528719.</mixed-citation><mixed-citation xml:lang="ru">Morrow M., Van Zee., Solin L. et al. Society of Surgical Oncology – American Society for Radiation Oncology – American Society of Clinical Oncology consensus Guideline on margins for breast-conserving surgery with wholebreast irradiation in ductal carcinoma in situ. J Clin Oncol 2016;34(33):4040–6. DOI: 10.1200/JCO.2016.68.3573. PMID: 27528719.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">9. Guidi A.J., Connolly J.L., Harris J.R. et al. The relationship between shaved margin and inked margin status in breast excision specimens. Cancer 1997;79(8):1568–73.PMID: 9118040.</mixed-citation><mixed-citation xml:lang="ru">Guidi A.J., Connolly J.L., Harris J.R. et al. The relationship between shaved margin and inked margin status in breast excision specimens. Cancer 1997;79(8):1568–73.PMID: 9118040.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">10. Kim K., Jung S.Y., Shin K.H. et al. Recurrence outcomes after omission of postoperative radiotherapy following breast-conserving surgery for ductal carcinoma in situ of the breast: a multicenter, retrospective study in Korea (KROG 16-02). Cancer Res Treat 2017;162:77–83.DOI: 10.1200/JCO.2009.21.8560. PMID: 19826126.</mixed-citation><mixed-citation xml:lang="ru">Kim K., Jung S.Y., Shin K.H. et al. Recurrence outcomes after omission of postoperative radiotherapy following breast-conserving surgery for ductal carcinoma in situ of the breast: a multicenter, retrospective study in Korea (KROG 16-02). Cancer Res Treat 2017;162:77–83.DOI: 10.1200/JCO.2009.21.8560. PMID: 19826126.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">11. Fisher E.R., Dignam J., Tan-Chiu E. et al. Pathologic findings from the national surgical adjuvant breast project (NSABP) eight-year update of Protocol B-17. Cancer 1999:86(3):429–38. PMID: 10430251.</mixed-citation><mixed-citation xml:lang="ru">Fisher E.R., Dignam J., Tan-Chiu E. et al. Pathologic findings from the national surgical adjuvant breast project (NSABP) eight-year update of Protocol B-17. Cancer 1999:86(3):429–38. PMID: 10430251.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">12. Hughes L.L., Wang M., Page D.L. et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009;27(32):5319–24. DOI: 10.1200/JCO.2009.21.8560. PMID: 19826126.</mixed-citation><mixed-citation xml:lang="ru">Hughes L.L., Wang M., Page D.L. et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009;27(32):5319–24. DOI: 10.1200/JCO.2009.21.8560. PMID: 19826126.</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">13. Solin L.J., Gray R., Hughes L.L. et al. Surgical excision without radiation for ductal carcinoma in situ of the breast: 12-year results from the ECOG-ACRIN E5194 Study. J Clin Oncol 2015;33(33):3938–44. DOI: 10.1200/JCO.2015.60.8588. PMID: 26371148.</mixed-citation><mixed-citation xml:lang="ru">Solin L.J., Gray R., Hughes L.L. et al. Surgical excision without radiation for ductal carcinoma in situ of the breast: 12-year results from the ECOG-ACRIN E5194 Study. J Clin Oncol 2015;33(33):3938–44. DOI: 10.1200/JCO.2015.60.8588. PMID: 26371148.</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">14. Motwani S.B., Goyal S., Moran M.S. et al. Ductal carcinoma in situ treated with breast-conserving surgery and radiotherapy: a comparison with ECOG Study 5194. Cancer 2011;117:1156–62. DOI: 10.1002/cncr.25623. PMID: 21381008.</mixed-citation><mixed-citation xml:lang="ru">Motwani S.B., Goyal S., Moran M.S. et al. Ductal carcinoma in situ treated with breast-conserving surgery and radiotherapy: a comparison with ECOG Study 5194. Cancer 2011;117:1156–62. DOI: 10.1002/cncr.25623. PMID: 21381008.</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">15. Goyal S., Vicini F., Beitsch D. et al. Ductal carcinoma in situ treated with breast-conserving surgery and accelerated partial breast irradiation: comparison of the Mammosite Registry trial with Intergroup Study E5194. Cancer 2011;117(6):1149–55. DOI: 10.1002/cncr.25615. PMID: 21381007.</mixed-citation><mixed-citation xml:lang="ru">Goyal S., Vicini F., Beitsch D. et al. Ductal carcinoma in situ treated with breast-conserving surgery and accelerated partial breast irradiation: comparison of the Mammosite Registry trial with Intergroup Study E5194. Cancer 2011;117(6):1149–55. DOI: 10.1002/cncr.25615. PMID: 21381007.</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">16. Fisher B., Dignam J., Wolmark N. et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomized controlled trial. Lancet 1999;353(9169):1993–2000. DOI: 10.1016/S0140-6736(99)05036-9. PMID: 10376613.</mixed-citation><mixed-citation xml:lang="ru">Fisher B., Dignam J., Wolmark N. et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomized controlled trial. Lancet 1999;353(9169):1993–2000. DOI: 10.1016/S0140-6736(99)05036-9. PMID: 10376613.</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">17. Wapnir I.L., Dignam J.J., Fisher B. et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst 2011;103(6):478–88. DOI: 10.1093/jnci/djr027. PMID: 21398619.</mixed-citation><mixed-citation xml:lang="ru">Wapnir I.L., Dignam J.J., Fisher B. et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst 2011;103(6):478–88. DOI: 10.1093/jnci/djr027. PMID: 21398619.</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">18. Houghton J., George W.D., Cuzick J. et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia and New Zealand: randomized controlled trial. Lancet 2003;1362(9378): 95–102. PMID: 12867108.</mixed-citation><mixed-citation xml:lang="ru">Houghton J., George W.D., Cuzick J. et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia and New Zealand: randomized controlled trial. Lancet 2003;1362(9378): 95–102. PMID: 12867108.</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">19. Forbes J.F., Sestak I., Howell A. et al. IBIS-II investigators. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomized controlled trial. Lancet 2016;387(10021):866–73. DOI: 10.1016/S0140-6736(15)01129-0. PMID: 26686313.</mixed-citation><mixed-citation xml:lang="ru">Forbes J.F., Sestak I., Howell A. et al. IBIS-II investigators. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomized controlled trial. Lancet 2016;387(10021):866–73. DOI: 10.1016/S0140-6736(15)01129-0. PMID: 26686313.</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">20. Margolese R.G., Cecchini R.S., Julian T.B. et al. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plusradiotherapy (NSABP B-35): a randomized, double-blind, phase 3 clinical trial. Lancet 2016;387(10021): 849–56. DOI: 10.1016/S0140-6736(15)01168-X. PMID: 26686957.</mixed-citation><mixed-citation xml:lang="ru">Margolese R.G., Cecchini R.S., Julian T.B. et al. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plusradiotherapy (NSABP B-35): a randomized, double-blind, phase 3 clinical trial. Lancet 2016;387(10021): 849–56. DOI: 10.1016/S0140-6736(15)01168-X. PMID: 26686957.</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">21. Li C.I., Anderson B.O., Daling J.R. et al. Changing incidence of lobular carcinoma in situ of the breast. Breast Cancer Res Treat 2002;75(3):259–68. PMID: 12353815.</mixed-citation><mixed-citation xml:lang="ru">Li C.I., Anderson B.O., Daling J.R. et al. Changing incidence of lobular carcinoma in situ of the breast. Breast Cancer Res Treat 2002;75(3):259–68. PMID: 12353815.</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">22. Carder P.J., Shaaban A., Alizadeh Y. et al. Screen-detected pleomorphic lobular carcinoma in situ (PLCIS): risk of concurrent invasive malignancy following a core biopsy diagnosis. Histopathology 2010;57(3):472–8. DOI: 10.1111/j.1365-2559.2010.03634.x. PMID: 20727019.</mixed-citation><mixed-citation xml:lang="ru">Carder P.J., Shaaban A., Alizadeh Y. et al. Screen-detected pleomorphic lobular carcinoma in situ (PLCIS): risk of concurrent invasive malignancy following a core biopsy diagnosis. Histopathology 2010;57(3):472–8. DOI: 10.1111/j.1365-2559.2010.03634.x. PMID: 20727019.</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><citation-alternatives><mixed-citation xml:lang="en">23. Brown K. Breast cancer chemoprevention: risk-benefit effects of the antioestrogen tamoxifen. Expert Opin Drug Saf 2002;1(3):253–67. PMID: 12904141.</mixed-citation><mixed-citation xml:lang="ru">Brown K. Breast cancer chemoprevention: risk-benefit effects of the antioestrogen tamoxifen. Expert Opin Drug Saf 2002;1(3):253–67. PMID: 12904141.</mixed-citation></citation-alternatives></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">24. Chuba P.J., Hamre M.R., Yap J. et al. Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data. J Clin Oncol 2005;23(24): 5534–41. DOI: 10.1200/JCO.2005.04.038. PMID: 16110014.</mixed-citation><mixed-citation xml:lang="ru">Chuba P.J., Hamre M.R., Yap J. et al. Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data. J Clin Oncol 2005;23(24): 5534–41. DOI: 10.1200/JCO.2005.04.038. PMID: 16110014.</mixed-citation></citation-alternatives></ref><ref id="B25"><label>25.</label><citation-alternatives><mixed-citation xml:lang="en">25. Rosen P.P. Axillary lymph node metastases in patients with occult noninvasive breast carcinoma. Cancerи 1980;46(5):1289–306. PMID: 6260331.</mixed-citation><mixed-citation xml:lang="ru">Rosen P.P. Axillary lymph node metastases in patients with occult noninvasive breast carcinoma. Cancerи 1980;46(5):1289–306. PMID: 6260331.</mixed-citation></citation-alternatives></ref><ref id="B26"><label>26.</label><citation-alternatives><mixed-citation xml:lang="en">26. Flanagan M.R., Rendi M.H., Calhoun K.E. et al. Pleomorphic lobular carcinoma in situ: radiologic-pathologic features and clinical management. Ann Surg Oncol 2015;22(13):4263–9. DOI: 10.1245/s10434-015-4552-x. PMID: 25893410.</mixed-citation><mixed-citation xml:lang="ru">Flanagan M.R., Rendi M.H., Calhoun K.E. et al. Pleomorphic lobular carcinoma in situ: radiologic-pathologic features and clinical management. Ann Surg Oncol 2015;22(13):4263–9. DOI: 10.1245/s10434-015-4552-x. PMID: 25893410.</mixed-citation></citation-alternatives></ref><ref id="B27"><label>27.</label><citation-alternatives><mixed-citation xml:lang="en">27. Fisher B., Constantino J.P, Wickerham D.L. et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90(18):1371–88. PMID: 9747868.</mixed-citation><mixed-citation xml:lang="ru">Fisher B., Constantino J.P, Wickerham D.L. et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90(18):1371–88. PMID: 9747868.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
